Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality  Sarah Caspersen, Margarita Elkjaer, Lene Riis, Natalia Pedersen, Christian Mortensen, Tine Jess, Pernille Sarto, Tanja S. Hansen, Vibeke Wewer, Flemming Bendtsen, Flemming Moesgaard, Pia Munkholm  Clinical Gastroenterology and Hepatology  Volume 6, Issue 11, Pages 1212-1217 (November 2008) DOI: 10.1016/j.cgh.2008.05.010 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Infusion reactions after treatment with infliximab. Others: infusion reactions that included conjunctiva injection, heat sensations, bradycardia, or swelling of cheek, joint, forearm, or hand. *This patient had a previous paresis of the facial nerve, which relapsed temporarily during the first 24 hours after the infliximab infusion. ☐, Number of reactions; , number of patients. Clinical Gastroenterology and Hepatology 2008 6, 1212-1217DOI: (10.1016/j.cgh.2008.05.010) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 Characteristics of 4 patients who developed cancer after treatment with infliximab. Clinical Gastroenterology and Hepatology 2008 6, 1212-1217DOI: (10.1016/j.cgh.2008.05.010) Copyright © 2008 AGA Institute Terms and Conditions

Figure 3 Characteristics of 13 patients who died during the follow-up evaluation after treatment with infliximab. *1, autopsy revealed no cause; *2, during explorative laparotomy; *3, during explorative laparotomy, suffered from pneumonia and pulmonal hypertension. Clinical Gastroenterology and Hepatology 2008 6, 1212-1217DOI: (10.1016/j.cgh.2008.05.010) Copyright © 2008 AGA Institute Terms and Conditions